KYNB

KYNB screens optically cheap — a 0.2 P/E and a $183M FY2025 net income — but both figures are mirages. The profit is non-operating: the MD&A ties it to the August 2025 sale of the China roxadustat business to AstraZeneca for $220.4M ($85.0M enterprise value + $135.4M net China cash). Strip that out and the real engine is operating income of -$45.9M (a -712.7% operating margin) on revenue that has cratered from $235M (FY2021) to just $6.44M (FY2025, -78.3% YoY), of which only ~$5.8M was API drug-product sales to Astellas. This is no longer a commercial-stage company; it is a clinical-stage oncology/anemia developer that has sold its one revenue-generating franchise.

The balance sheet is impaired. Stockholders' equity is NEGATIVE -$30.0M (liabilities/equity -3.83x), accumulated deficit is -$1.71B, and $47.9M of cash sits against $75.0M long-term debt plus a $67.3M NovaQuest RIFA liability (a sale of future revenues that anticipates a payment cap of up to $125.0M by 2031) and $11.1M+ of TEKES loans. Management states plainly it 'will need substantial additional funding in connection with our continuing operations' — the classic prelude to dilution, made more acute by a float of only 4.05M shares after a ~96% share-count reduction (a reverse split that also inflates the $45.37 EPS optics).